Abstract: The present disclosure relates to a composition for tagatose production and a method for preparing tagatose using the same.

Abstract: Provided are a novel composition for preparing allulose and a method of preparing allulose using the same.

Abstract: Disclosed is a thermoplastic resin composition, a method of preparing the same, and a molded article including the same, including a thermoplastic resin composition including 100 parts by weight of a base resin including 20 to 90% by weight of a non-recycled thermoplastic resin (A) and 10 to 80% by weight of a recycled thermoplastic resin (B); 1 to 10 parts by weight of an ethylene compound-vinyl acetate compound copolymer (C); and 0.01 to 10 parts by weight of an inorganic pigment (D), wherein the inorganic pigment (D) has a refractive index of 1.65 or more and an average particle diameter of 10 to 500 nm.

Abstract: The present application relates to a fructose-4-epimerase variant exhibiting tagatose conversion activity and a method for preparing tagatose using the same.

Abstract: Disclosed is a thermoplastic resin composition having excellent compatibility between a base resin and additives that may prevent aggregation of a metal pigment, and a molded article including the same. Also disclosed is a molded article manufactured using the thermoplastic resin composition, which may reduce flow marks on a metallic surface, and thus appearance and gloss may be excellent, injection quality and antistatic properties may be excellent, and the molded article may be widely used in various fields such as electronics.

Abstract: The present disclosure relates to novel fructose-C4-epimerase and a method of preparing tagatose using the same.

Abstract: Provided is a thermoplastic resin composition that includes: a first copolymer including an unit derived from an aromatic vinyl-based monomer and an unit derived from a vinyl cyan-based monomer; a second copolymer including an unit derived from an alkyl (meth)acrylate-based monomer, an unit derived from an aromatic vinyl-based monomer, and an unit derived from a vinyl cyan-based monomer; a third copolymer including a conjugated diene-based polymer with an average particle diameter of 0.25 to 0.35 ?m, an unit derived from an aromatic vinyl-based monomer, and an unit derived from a vinyl cyan-based monomer; and a fourth copolymer including a conjugated diene-based polymer with an average particle diameter of 0.05 to 0.15 ?m, an unit derived from an aromatic vinyl-based monomer, and an unit derived from a vinyl cyan-based monomer, and can be used for producing a molded article exhibiting excellent basic properties while being capable of realizing selective transmittance.

Abstract: The present disclosure is a pharmaceutical composition for the prevention or treatment of sepsis containing a thiamine derivative or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition of the present disclosure can be used for the prevention, alleviation, or treatment of sepsis by containing fursultiamine or allithiamine to inhibit the expressions of CD40, CD86, and TNF?.

Abstract: The present disclosure relates to novel D-psicose 3-epimerase and a method for producing psicose using the same.

Abstract: Provided are a fructose-4-epimerase variant having tagatose conversion activity, and a method of producing tagatose using the same.

Abstract: Provided are a composition for producing tagatose, comprising fructose-4-epimerase, and a method of producing tagatose using the same.

Abstract: The present disclosure relates to a composition for producing tagatose comprising a protein having fructose-4-epimerase activity and a method for producing tagatose using the same.

Abstract: Provided is a method for coating an implant using heat, and more particularly to a method for coating only the surface of an implant with a biocompatible polymer by using heat while maintaining physical characteristics of the implant. The method for coating an implant using heat according to the present invention may effectively introduce a biocompatible polymer onto a three-dimensional material surface and thus may overcome the spatial limitations of light, and enables mass-coating and thus may be effectively used in the manufacture of an implant coated with a biocompatible polymer.

Abstract: The present disclosure relates to a composition for producing glucosylated steviol glycoside, the composition including glucosyltransferase including an amino acid sequence of SEQ ID NO: 1; and a method of producing glucosylated steviol glycoside using the same.

Abstract: Disclosed is a thermoplastic resin composition including a base resin having a diene-based rubber graft copolymer and a vinyl cyanide-aromatic vinyl-based copolymer, an olefin-based copolymer having a crystalline unit, and a metallic pigment.

Abstract: The present disclosure relates to a mixed sugar composition containing tagatose and sorbose.

Abstract: The present application relates to a microorganism that produces allulose and a method for preparing allulose using the same.

Abstract: The present disclosure relates to a method for preparing a transfructosylated steviol glycoside using Arthrobacter-derived microorganisms, a culture thereof, a supernatant of the culture, an extract of the culture, and a lysate of the microorganisms.

Abstract: The present invention relates to a sweetening material composition and a method for preparing the same. Specifically, the present invention relates to a sweetening material composition including transglycosylation steviol glycosides and a method for preparing the same. The sweetening material composition of the present invention includes transglycosylated stevia and saccharides, and the saccharides include 5 to 90 parts by weight of an oligosaccharide having a degree of polymerization (DP) of 3 or more with respect to 100 parts by weight.

Abstract: A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject.